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Abstract
Background: Oxidative stress plays an important role in the course and eventual outcome in a majority of patients 
admitted to the intensive care unit (ICU). Markers to estimate oxidative stress are not readily available in a clinical 
setting. AGEs accumulation has been merely described in chronic conditions, but can also occur acutely due to 
oxidative stress. Since AGEs have emerged to be stable end products, these can be a marker of oxidative stress. Skin 
autofluorescence (AF) is a validated marker of tissue content of AGEs. We hypothesized that AGEs accumulate acutely 
in ICU patients.
Methods: We performed an observational prospective study in a medical surgical ICU in a university affiliated teaching 
hospital. All consecutively admitted ICU patients in a 2 month period were included. Skin AF was measured using an 
AGE reader in 35 consecutive ICU patients > 18 yrs. As a comparison, historical data of a control group (n = 231) were 
used. These were also used to calculate age-adjusted AF-levels (AFadj). Values are expressed as median and interquartile 
range [P25-P75]. Differences between groups were tested by non parametric tests. P < 0.05 was considered statistically 
significant.
Results: AFadj values were higher in ICU patients (0.33 [0.00 - 0.68]) than in controls (-0.07 [-0.29 - 0.24]; P < 0.001). No 
differences in skin AFadj were observed between acute or planned admissions, or presence of sepsis, nor was skin AFadj 
related to severity of disease as estimated by APACHE-II score, length of ICU, hospital stay or mortality.
Conclusion: Acute AGE accumulation in ICU patients was shown in this study, although group size was small. This can 
possibly reflect oxidative stress in ICU patients. Further studies should reveal whether AGE-accumulation will be a 
useful parameter in ICU patients and whether skin AF has a predictive value for outcome, which was not shown in this 
small study.
Background
Patients admitted to the intensive care unit (ICU) may
develop multiple organ dysfunction syndrome (MODS).
The pathogenesis of this deterioration of organ function
involves oxidative stress caused by reactive oxygen spe-
cies (ROS) [1]. Indeed, the prognosis and outcome of
patients admitted to the ICU is dependent on the degree
of oxidative stress [2]. Oxidative stress is associated with
most conditions requiring intensive care: but how could
oxidative stress be measured? Interestingly, no common
strategy exists about its measurement and many methods
of estimating oxidative stress have proven unreliable [3].
Moreover most parameters need complicated blood sam-
ple measurements.
Advanced glycation endproducts (AGEs) accumulate
with oxidative stress and can be very easily and quickly
measured, non-invasively. AGEs comprise a diverse class
of compounds that link to proteins and accumulate in
long-lived tissues. Several AGEs encompass a character-
istic autofluorescence pattern when illuminating skin [4].
Using this specific property; skin AGE accumulation can
be assessed by the AGE reader, a non-invasive, quick
method, that has been thoroughly validated with AGEs
measured in skin biopsies [4]. AGEs can be formed by
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several pathways [5]. In addition to the classical pathway,
known as the Maillard reaction, other pathways are
important, such as formation by reactive carbonyl com-
pounds, which may form rapidly under oxidative stress
[6]. In contrast to most other markers of oxidative stress,
AGEs, once formed are stable compounds. They accumu-
late with age and play an important role in the develop-
ment of end organ damage in several conditions such as
diabetes, atherosclerosis and renal failure [7-9]. Two
mechanisms may play a role. First, AGE modification
directly alters the function and structure of extracellular
matrix proteins [10]. Second, AGEs modulate cellular
functions through ligation of specific cell surface recep-
tors, such as the receptor for AGEs (RAGE) [11].
AGE accumulation has been described merely in
chronic diseases. But since oxidative stress also augments
AGE formation, and oxidative stress occurs in patients in
the ICU, we hypothesize an acute rise of AGE levels in
patients admitted to the ICU.
Methods
Design
This observational study, without interference with usual
care was carried out in a university affiliated teaching
hospital with an ICU with a mixed medical-surgical
closed-format setting with 10 beds. Due to the observa-
tional nature of the study without changes in therapy, the
requirement for obtaining informed consent was waived
by the institutional review board.
AGE measurements
AGE levels were measured with the AGE-reader, a non-
invasive, portable device, which has been thoroughly vali-
dated with AGEs measured in skin biopsies [4], DiagnOp-
tics BV, Groningen, the Netherlands. All measurements
were performed within 24 hours after admission, consis-
tently by the same observer (WLG). The AGE-reader illu-
minates a skin surface of 1 cm2, with an excitation light
source between 300-420 nm. Only light from the skin is
measured with a spectrometer in the 300-600 nm range,
using 200 um glass fiber. Autofluorescence (AF) will be
calculated as follows: ratio between average light inten-
sity, measured in the range 420 - 600 nm and the average
light intensity in the range 300-420 nm (emission/excita-
tion) and this ratio is expressed as arbitrary units. Three
consecutive measurements, from each patient were taken
of which the mean was calculated.
Patients
Patients were included if skin AF could be measured
within 24 hrs after admission. Patients with coloured skin
were excluded, because the AGE reader had not yet been
validated in patients with coloured skin. Patients with
diabetes, liver cirrhosis or renal clearance below 35 ml/
min were also excluded, because these conditions are
known to cause AGE accumulation.
Controls
A formerly studied group of healthy volunteers (231 indi-
viduals, seen in the outpatient clinic for preoperative
evaluation without a history of diabetes, cardiovascular
events or renal disease, and all within ASA Class I or II
criteria) was used to verify normal AGE levels in healthy
individuals (see reference [12] for details)[12]. AGE data
were plotted against calendar age to yield a standard skin
AF level for each age since AGEs accumulate with age
(figure 1). Subsequently, the age-adjusted skin AF (AFadj)
was calculated according the following formula: skin
AFadj level = skin AF measured - (0.9378 + (0.0233 * age))
for both patients and controls. After the calculation the
skin AFadj level for controls approaches zero.
Statistics
Statistical analyses were performed using SPSS 9.5 for
WINDOWS. Non parametric tests were applied. All val-
ues are expressed as (median [interquartile range; P25 -
P75]). A P-value < 0.05 was defined to indicate statistical
significance.
Results
Patients
Thirty-five consecutive ICU patients, 21 male, 14 female
were included. The median age in patients was 74 years
[57 - 80]. Patient characteristics are shown in table 1.
AP ACHE-II scores as well as length of stay in the ICU
were comparable to a one year period preceding this
study (data not shown).
Skin autofluorescence measurements
Absolute skin AF levels were higher in ICU patients (2.81
[2.28-3.34]) as compared to controls (2.07 [1.74-2.47]; P <
0.001). However, ICU patients were older (74 [57-80
years]) than control subjects (51 [39-67 years]; P < 0.001).
In view of the established relation between AGE-levels
and calendar age, all further analyses were based on skin
AFadj (adjusted for age). After the correction for age, skin
AFadj was still higher in patients admitted to the ICU
(0.33 [0.00 - 0.68]) than in controls (-0.07 [-0.29 - 0.24]; P
< 0.001) (figure 2).
Associations with other parameters
No associations were found between skin AF-adj and dis-
ease severity as estimated by APACHE-II scores (R =
0.068), ICU length of stay (R = 0.004|), mortality (p =
0.905), nor with sepsis during ICU stay (p = 0.18), the rea-
son for ICU admission (p = 0.544) or the urgency of
admission (p = 0.292). In addition, no associations could
be found between skin AF-adj and levels of albumin (R =Greven et al. BMC Clinical Pathology 2010, 10:4
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0.036), highest glucose level (R = 0.016) or the lowest pH
(R = 0.00) in the first 24 hours of ICU stay.
Discussion
This study shows acute AGE accumulation in ICU
patients in a direct way by skin auto fluorescence. In this
study the accumulation was not associated with disease
severity, ICU length of stay or mortality.
Acute AGE accumulation is most likely mediated by
oxidative stress, as the classical Maillard reaction is a slow
non-enzymatic reaction. Oxidative stress causes forma-
tion of reactive carbonyl compounds, which react with
protein to form AGEs [6]. Also blocking nitric oxide
activity causes the production of reactive oxygen species
[13]. Moreover binding of AGEs to RAGE generates
intracellular reactive oxygen species [14,15]. This results
in diminished reduced glutathione, and ascorbic acid.
Depletion of glutathione leads to reduced glyoxalase-1
recycling and decreased in situ activity. Glyoxalase-1,
however, has an important role in reducing the cellular
AGE load [16,17]. Hence, an acute event could result in
acute oxidative stress in the ICU patient, concomitant
AGE accumulation, which itself could cause more oxida-
tive stress, thus potentially causing a vicious cycle with
progressive multiple organ failure.
The question is whether AGE accumulation is harmful?
At least when evaluating chronic accumulation, AGE lev-
els predict future microvascular and cardiovascular
events in diabetic patients better than HbA1c [8,9,18].
Moreover skin AGE accumulation predicts (cardiovascu-
lar) mortality in hemodialysis patients and in patients
with type 2 diabetes [7,19]. In addition, interventions
aiming to modulate AGE accumulation have proved to
alleviate end-organ damage in animal models [20]. This
may support the idea about AGEs playing a causal and
potentially predictive role in end organ damage. In con-
trast to these chronic accumulation of AGEs, recent
research is focussed on the less known acute AGE accu-
mulation. One may hypothesize that this acute AGE
a c c u m u l a t i o n ,  a s  s e e n  i n  o u r  s t u d y ,  m a y  b e  h a r m f u l
because of intracellular ROS formation as well as deple-
tion of antioxidant mechanisms [15,16]. In ICU patients,
one study showed elevated levels of soluble AGE recep-
tors (sRAGE) at admission in septic patients [21]. Fur-
thermore, application of an extracellular decoy for RAGE
ligands, improves survival in mice after induction of sep-
sis, suggesting that RAGE is a central player in perpetuat-
ing the innate immune response [22]. Also, AGEs content
measured in pericardial fluids seemed to have a prognos-
tic factor after cardiac surgery [23] and plasma levels of
sRAGE was associated with increased severity of lung
injury and increased mortality in patients with acute lung
injury [24]. In addition, plasma sRAGE levels predicted
length of stay in ICU in patients after lung transplanta-
Figure 1 Skin AF levels in control subject show a linear correlation with age, according to an equation: skin AF level = 0.9378 + (0.0233 * 
age) (R2 = 0.43).Greven et al. BMC Clinical Pathology 2010, 10:4
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tion [25]. This is in concordance with our data finding
elevated AGE levels already at admission in comparison
to control subjects. However, we were not able to find an
association with disease severity, ICU length of stay, nor
with mortality. Besides differences in case mix and mor-
tality rate, this difference might be explained by the fact
that plasma sRAGE levels are not reflecting actual AGE
accumulation, thus yielding different results. We did not
measure plasma sRAGE in our patients. More research,
with larger numbers of patients, and in defined sub-
groups, should be carried out to address these issues.
Several study limitations need to be addressed. First,
this is a small, single center study. Hence, the results may
be quite different in other case-mixes in other ICUs. Sec-
ondly, this is a small series of patients. Nevertheless, they
are probably a reasonable reflection of admissions to our
ICU, because the composition of the patient characteris-
tics did not differ with those in a 1 year period preceding
this study. Thirdly, the AGE reader itself has not been for-
mally validated for use in an ICU setting since all previ-
ous studies have been done in outclinic patients. One
might argue that factors like edema could have influenced
the results. Indeed, because water is not autofluorescent,
values could be mildly reduced in the presence of sub-
stantial edema in the arm that was measured. However,
this should be structurally addressed in further studies.
Fourth; patients with conditions, known to cause AGE
accumulation were not included in this study . So AGE
accumulation is therefore most likely caused by the ICU
admission itself. But the design of this study was cross-
s e c t i o n a l ,  s o  s k i n  A F  v a l u e s  b e f o r e  I C U  a d m i s s i o n  o f
these particular patients are unknown. Further studies,
should maybe focus on longitudinal skin AF measure-
ments to show acute accumulation with ICU admission
in the same patient.
In conclusion, acute AGE accumulation occurs in ICU
patients, which probably reflects oxidative stress. The
group was too small to allow any conclusions on the pos-
sible predictive value of skin AF for prognosis for patients
on the ICU. Further studies should reveal whether mea-
surement of AGE-accumulation will be a useful parame-
ter in ICU patients.
Conclusion
Acute AGE accumulation was shown in this small group
of ICU patients, which probably reflects oxidative stress.
The group was too small to allow any conclusions on the
possible predictive value of skin AFadj for outcome. Fur-
ther studies should reveal whether AGE-accumulation
will be a useful parameter in ICU patients.
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Table 1: Patient characteristics
ICU patients
N3 5
Age (years) 74 [57 - 80]
Skin AF level 2.81 [2.28 - 3.34]
Skin AF-adj 0.33 [0.00 - 0.68]
ICU LOS (days) 3.00 [2.00 - 6.25]
hospital LOS (days) 13.50 [8.50 - 24.25]
APACHE II 13.0 [10.0 - 16.0]
% died, during ICU-stay 14.3%
% ventilated 94.3%
Admission type
% acute medical 17.1%
% acute surgical 40.0%
% planned 42.9%
First 24 hrs of ICU stay
highest glucose level (mmol/l) 8.5 [6.5-11.9]
lowest pH 7.41 [7.36-7.44]
lowest albumin (g/l) 22 [15-24]
LOS = length of stay (days)
Values are expressed as median and IQR [P25 - P75] or percentages
Figure 2 Boxplots with median, P25 and P75 The whiskers indicate 
P95 and P5 of skin AF adjusted for age (AFadj) in controls and ICU 
patients. AU = arbitrary units.
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